Abstract
This paper is an account of a Phase III placebo-controlled clinical evaluation of an experimental treatment for stroke. The motivation for choosing a sequential design is discussed, as well as the technique for determining the triangular stopping boundaries used. The primary patient response was an ordinal performance scale evaluated three months after treatment. Plans made for incorporating delayed observations and baseline evaluations into the analysis are described.
The trial has now been completed. The conduct of the interim and final analyses are described, and the study results and conclusions presented.
Get full access to this article
View all access options for this article.
